Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 21, 2020 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Present at the Cowen 40th Annual Healthcare Conference

PITTSBURGH, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients...
January 24, 2020 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Breaks Ground On Second Commercial Gene Therapy Manufacturing Facility

PITTSBURGH, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a gene therapy company developing medicines to treat rare diseases, announced today the ground breaking of the...
January 21, 2020 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Appoints Jennifer Chien as Chief Commercial Officer

PITTSBURGH, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a gene therapy company developing medicines to treat rare diseases, today announced the appointment of Jennifer...
November 26, 2019 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Present at the Piper Jaffray 31st Annual Healthcare Conference

PITTSBURGH, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients...
November 04, 2019 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Reports Third Quarter 2019 Financial and Operating Results

Alignment With FDA on GMP Commercial Manufacturing Process for KB103 (Bercolagene telserpavec, “B-VEC”)KB105 Granted Fast Track Designation by the FDAPlatform Patent for Delivering any Effector to the...
October 29, 2019 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Final Update from Phase 1/2 Clinical Trial of KB103 ("bercolagene telserpavec," "B-VEC")

Safety data from all patients (Phase 1 and Phase 2) show that B-VEC was well tolerated with no related adverse events reported.Nine out of 10 of the wounds closed completely (100% closure) following...
October 10, 2019 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Receives Positive EMA Opinion on Orphan Designation for KB105 to Treat Patients With TGM1 Deficient Autosomal Recessive Congenital Ichthyosis

PITTSBURGH, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases, today announced that...
September 30, 2019 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Present at the Cantor 2019 Global Healthcare Conference and Chardan's 3rd Annual Genetic Medicines Conference

PITTSBURGH, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients...
September 27, 2019 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Granting of its First Foreign Patent and Reinforces its IP Portfolio with a New U.S. Patent

PITTSBURGH, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients...
September 04, 2019 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Initiation of Phase 1/2 Study of KB105 in Transglutaminase-1 (“TGM1”) Deficient Autosomal Recessive Congenital Ichthyosis (“ARCI”)

PITTSBURGH, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases, today announced the...